$59.65
3.67% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US40637H1095
Symbol
HALO

Halozyme Therapeutics, Inc. Stock price

$61.92
+3.96 6.83% 1M
+1.49 2.47% 6M
+14.11 29.51% YTD
+21.69 53.92% 1Y
+20.09 48.03% 3Y
+45.67 281.05% 5Y
+47.24 321.65% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-1.10 1.75%
ISIN
US40637H1095
Symbol
HALO
Sector
Industry

Key metrics

Market capitalization $7.65b
Enterprise Value $8.59b
P/E (TTM) P/E ratio 18.04
EV/FCF (TTM) EV/FCF 18.34
EV/Sales (TTM) EV/Sales 8.46
P/S ratio (TTM) P/S ratio 7.53
P/B ratio (TTM) P/B ratio 20.96
Revenue growth (TTM) Revenue growth 22.44%
Revenue (TTM) Revenue $1.02b
EBIT (operating result TTM) EBIT $551.48m
Free Cash Flow (TTM) Free Cash Flow $468.37m
Cash position $596.07m
EPS (TTM) EPS $3.43
P/E forward 14.16
P/S forward 6.40
EV/Sales forward 7.19
Short interest 11.15%
Show more

Is Halozyme Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Halozyme Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

Buy
63%
Hold
38%

Financial data from Halozyme Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,015 1,015
22% 22%
100%
- Direct Costs 230 230
13% 13%
23%
785 785
39% 39%
77%
- Selling and Administrative Expenses 73 73
13% 13%
7%
- Research and Development Expense 79 79
4% 4%
8%
633 633
50% 50%
62%
- Depreciation and Amortization 81 81
4% 4%
8%
EBIT (Operating Income) EBIT 551 551
63% 63%
54%
Net Profit 444 444
58% 58%
44%

In millions USD.

Don't miss a Thing! We will send you all news about Halozyme Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Halozyme Therapeutics, Inc. Stock News

Neutral
Investors Business Daily
about 4 hours ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
PRNewsWire
4 days ago
A decision on the European marketing authorization extension for the subcutaneous formulation of Opdivo is expected by June 2, 2025 SAN DIEGO , March 31, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, r...
Positive
FXEmpire
14 days ago
Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.
More Halozyme Therapeutics, Inc. News

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Helen Torley
Employees 350
Founded 1998
Website www.halozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today